stocks logo

HOWL

Werewolf Therapeutics Inc
$
1.370
-0.02(-1.439%)1D
  • Overview
  • Forecast
  • Valuation
  • Earnings
Line
Line
|
Candle
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
1.430
Open
1.400
VWAP
1.35
Vol
338.71K
Mkt Cap
61.48M
Low
1.250
Amount
457.78K
EV/EBITDA(TTM)
--
Total Shares
43.46M
EV
-3.08M
EV/OCF(TTM)
--
P/S(TTM)
53.67
Werewolf Therapeutics, Inc. is a biopharmaceutical company engaged in the development of therapeutics engineered to stimulate the body’s immune system for the treatment of cancer and other immune-mediated conditions. It is leveraging its PREDATOR platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. Its INDUKINE molecules are intended to remain inactive in peripheral tissue yet activate selectively in the tumor microenvironment. The Company’s advanced clinical-stage product candidates, WTX-124 and WTX-330, are systemically delivered, conditionally activated Interleukin-2 (IL-2) and IL-12 INDUKINE molecules for the treatment of solid tumors. It is advancing WTX-124 in multiple tumor types as a single agent and in combination with an immune checkpoint inhibitor. It is advancing WTX-712, WTX-518, and WTX-921 through preclinical development.
Show More

Market Estimates

Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2025Q3
FY2025Q2
300.00K
-59.57%
-0.393
-14.49%
--
--
-0.390
+2.63%
--
--
-0.373
-2.68%
Estimates Revision
The market is revising No Change the revenue expectations for Werewolf Therapeutics, Inc. (HOWL) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by 53.81%.
Revenue Estimates for FY2025
No Change
down Image
0.00%
In Past 3 Month
EPS Estimates for FY2025
No Change
down Image
0.00%
In Past 3 Month
Stock Price
Go Up
up Image
+53.81%
In Past 3 Month
5 Analyst Rating
up Image
498.54% Upside
Wall Street analysts forecast HOWL stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for HOWL is 8.20 USD with a low forecast of 4.00 USD and a high forecast of 12.00  USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
5 Buy
0 Hold
0 Sell
Strong Buy
up Image
498.54% Upside
Current: 1.370
sliders
Low
4.00
Averages
8.20
High
12.00
BofA
Buy
downgrade
$10 -> $9
2025-05-27
Reason
Wedbush
Outperform -> NULL
downgrade
$8 -> $6
2025-05-09
Reason
Wedbush lowered the firm's price target on Werewolf Therapeutics to $6 from $8 to adjust future financing expectations following the recent price decline, while keeping an Outperform rating on the shares following quarterly results and updates regarding PREDATOR-masked products. WTX-124 remains on track to report initial clinical data in the second half of 2025.
HC Wainwright & Co.
Andres Maldonado
Strong Buy
Reiterates
$15
2025-03-12
Reason
Wedbush
Robert Driscoll
Buy
Reiterates
$8
2025-03-12
Reason
JMP Securities
Reni Benjamin
Buy
Maintains
$12 → $4
2025-01-14
Reason
JMP Securities lowered the firm's price target on Werewolf Therapeutics (HOWL) to $4 from $12 and keeps an Outperform rating on the shares. Werewolf recently reported 2025 milestone updates, including WTX-124 dose expansion data expected in 4Q25 as well as the initiation of a study targeting WTX-330 to the tumor microenvironment, the analyst tells investors. With multiple data updates expected during 2025, a partnership with Jazz Pharmaceuticals (JAZZ), and a cash position at $122.8M, the firm says Werewolf represents an interesting investment opportunity at current levels.
HC Wainwright & Co.
Andres Maldonado
Strong Buy
Reiterates
$15
2024-11-19
Reason

Valuation Metrics

The current forward P/E ratio for Werewolf Therapeutics Inc (HOWL.O) is -0.88, compared to its 5-year average forward P/E of -3.24. For a more detailed relative valuation and DCF analysis to assess Werewolf Therapeutics Inc 's fair value, click here.

Forward PE

StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-3.24
Current PE
-0.88
Overvalued PE
-0.13
Undervalued PE
-6.35

Forward EV/EBITDA

StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-0.95
Current EV/EBITDA
-0.10
Overvalued EV/EBITDA
1.57
Undervalued EV/EBITDA
-3.48

Forward PS

StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
23.58
Current PS
0.00
Overvalued PS
49.76
Undervalued PS
-2.59

Financials

Annual
Quarterly
FY2025Q1
YoY :
-100.00%
0.00
Total Revenue
FY2025Q1
YoY :
+4.83%
-17.99M
Operating Profit
FY2025Q1
YoY :
+11.71%
-18.09M
Net Income after Tax
FY2025Q1
YoY :
+2.56%
-0.40
EPS - Diluted
FY2025Q1
YoY :
+22.98%
-18.95M
Free Cash Flow
FY2025Q1
YoY :
-100.00%
N/A
Gross Profit Margin - %
FY2025Q1
YoY :
+2098.30%
-5.25K
FCF Margin - %
FY2025Q1
YoY :
-100.00%
N/A
Net Margin - %

Trading Trends

Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
9.2K
USD
3
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
3
487.2K
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
398.9K
Volume
1
6-9
Months
493.3K
Volume
1
0-12
Months
0.0
Volume
0
Bought
0-3
1
92.6K
Volume
Months
3-6
0
0.0
Volume
Months
6-9
0
0.0
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months

HOWL News & Events

Events Timeline

2025-05-08 (ET)
2025-05-08
07:18:25
Werewolf Therapeutics reports Q1 EPS (40c), consensus (43c)
select
2025-05-05 (ET)
2025-05-05
08:13:50
Werewolf Therapeutics presents new preclinical data on IL-10 INDUKINE
select
2025-04-17 (ET)
2025-04-17
08:07:22
Werewolf Therapeutics appoints Bloom as Chief Business Officer
select
Sign Up For More Events

News

9.0
05-20Newsfilter
HonorHealth Research Institute patient with advanced skin cancer in remission for more than a year following clinical trial of Werewolf Therapeutics' investigational novel conditionally activated IL-2 pro-drug WTX-124
1.0
05-13Newsfilter
Werewolf Therapeutics to Participate in Hanson Wade's 6th Annual Cytokine-Based Drug Development Summit
4.0
05-09Benzinga
Wedbush Maintains Outperform on Werewolf Therapeutics, Lowers Price Target to $6
Sign Up For More News

FAQ

arrow icon

What is Werewolf Therapeutics Inc (HOWL) stock price today?

The current price of HOWL is 1.37 USD — it has decreased -1.44 % in the last trading day.

arrow icon

What is Werewolf Therapeutics Inc (HOWL)'s business?

arrow icon

What is the price predicton of HOWL Stock?

arrow icon

What is Werewolf Therapeutics Inc (HOWL)'s revenue for the last quarter?

arrow icon

What is Werewolf Therapeutics Inc (HOWL)'s earnings per share (EPS) for the last quarter?

arrow icon

What changes have occurred in the market's expectations for Werewolf Therapeutics Inc (HOWL)'s fundamentals?

arrow icon

How many employees does Werewolf Therapeutics Inc (HOWL). have?

arrow icon

What is Werewolf Therapeutics Inc (HOWL) market cap?